focus -WSS

focus

author：entertainment 2025-09-30 00:46:57 - browse：953

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Cancer researcher Catriona Jamieson is sending tumors into space

hotspot

WSS

Dark money group runs ads on China biotech bill

Orangutan used medicinal plant to treat wound, first time ever seen

Why does health care cost so much? A reading guide

iTeos Therapeutics debuts first data on TIGIT

Q&A: Jennifer Adair on making gene therapy available globally

Cancer researcher Catriona Jamieson is sending tumors into space

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Q&A: Jennifer Adair on making gene therapy available globally

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

MassMutual is introducing free genetic testing for members

Drug repurposing or repositioning? The language matters

H5N1 bird flu found in pasteurized milk: what we know

Peter Hotez and the public health issue of online harassment

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Moonlake's readout produced a cash windfall. Risks remain

Cell therapy fails to slow type 1 diabetes, but safety is established

entertainment

What will save rural psychiatry services? Higher Medicaid payments

Health insurers say they are turning to AI to cut costs, improve care

UnitedHealth financials solid despite Change Healthcare cyberattack

AI used to predict Covid

Dark money group runs ads on China biotech bill

Akili, maker of video game for ADHD, to be acquired for 34 million

entertainment

entertainment

hotspot

explore